Overview

Combined Vaginal Misoprostol and Perivascular Vasopressin

Status:
Recruiting
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
Injection of Vasopressin into the uterine tissue surrounding fibroids constricts blood vessels, and has been found to be beneficial by decreasing blood flow to fibroids, and thereby resulting in less bleeding with removal. Additionally, Misoprostol has been looked at as an additional method to decrease operative blood loss given its ability to increase uterine muscle tone, which therefore constricts the amount of blood flow to the uterus.
Phase:
Phase 4
Details
Lead Sponsor:
Maimonides Medical Center
Treatments:
Arginine Vasopressin
Misoprostol
Vasopressins